恶性胶质瘤生物学标志物的研究进展  

Biomarker of malignant glioma

作　　者：王子威[1] 贾秀志[1] 任欢[1] 

机构地区：[1]哈尔滨医科大学免疫学教研室,150081

出　　处：《国际免疫学杂志》2013年第3期170-173,共4页International Journal of Immunology

基　　金：国家自然科学基金（30772238）;国家自然科学基金重大研究计划培育项目（91229112）

摘　　要：当前恶性胶质瘤的诊断主要依靠影像学方法，以病理学检测确定肿瘤分期及恶性度。因为传统的手术、放疗和化疗的治疗方案效果不理想，近年来以胶质瘤相关分子标志物进行鉴别分类并评估其预后成为研究热点。肿瘤标志物在监测肿瘤的复发与转移，临床诊断与治疗等方面具有很高的应用价值，同时为研究肿瘤的发生与发展机制提供了新的方法。Until recently, treatment decisions regarding malignant gliomas began with establishing di- agnosis by standard imaging methods and determined tumor stage and grade by histopathology. Because the treatment effect of traditional surgery, radiotherapy and chemotherapy is not ideal, biomarkers researches to im- prove glioma subclassification and prognostic evaluation have become a hot spot. Tumor biomarkers have the very high application value in monitoring tumor recurrence and metastasis, helping clinical diagnosis and treat- ment, which also apply a new method to explore the mechanism of tumorigenesis and development.

关 键 词：恶性胶质瘤 分子病理 生物标志物 

分 类 号：R739.4[医药卫生—肿瘤]